Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prenylated Rab acceptor protein 1 (RABAC1, also known as PRA1) is a highly conserved, multi-pass integral membrane protein primarily localized to the Golgi apparatus and also found at endoplasmic reticulum (ER)–mitochondria membrane contact sites. RABAC1 binds prenylated Rab GTPases and helps direct their proper targeting to distinct membrane compartments, thereby regulating vesicular trafficking and protein transport[1][2]. It interacts with various proteins involved in cell signaling and trafficking, including α-synuclein and viral proteins, indicating its functional relevance to intracellular signaling, lipid metabolism, and potential disease processes. RABAC1 exhibits tumor-suppressive activity in certain contexts by promoting apoptosis and inhibiting cancer cell migration and proliferation. It is downregulated in models of retinal degeneration, highlighting a possible role in neurodegeneration. Despite early hypotheses of its function as a general Rab GTPase regulator, recent studies suggest it may also have specialized roles in lipid handling and maintenance of early secretory pathway integrity[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prenylated Rab acceptor protein 1 (RABAC1).